In adoptive cell therapy, using DCs treated with IL-2, PBMCs, KRASG12D1−23 peptide, or tumor lysates resulted in the increase of CD8+ T cells and decrease of TH1 cells, TGF-β and IL-10. The gene discussed is CD8A; the disease is neoplasm.